STOCK TITAN

Novavax Inc - NVAX STOCK NEWS

Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.

Novavax Inc (NVAX) is a clinical-stage biotechnology company pioneering vaccine development through recombinant nanoparticle technology and its proprietary Matrix-M adjuvant. This dedicated news hub provides investors and industry observers with timely updates on corporate developments, clinical trial progress, and regulatory milestones.

Our curated collection of Novavax news ensures access to official press releases, financial disclosures, and strategic partnership announcements. Users will find updates spanning vaccine candidate advancements, manufacturing expansions, and peer-reviewed research findings. Key content areas include quarterly earnings reports, FDA regulatory submissions, and global health collaborations.

Bookmark this page for streamlined tracking of Novavax's progress in addressing infectious diseases like COVID-19, influenza, and RSV. The resource is regularly updated to serve as your primary source for verified information about NVAX's scientific innovations and market positioning.

Rhea-AI Summary

Novavax, a biotechnology company focused on next-generation vaccines, will participate in Evercore ISI's 4th Annual HealthCONx Virtual Conference on December 2, 2021, from 9:15 to 9:35 a.m. ET. The discussion will center on NVX-CoV2373, their protein-based COVID-19 vaccine. Participants include Gregory M. Glenn, M.D., and John J. Trizzino. Investors can access a replay of the fireside chat on Novavax's website for 90 days post-event. Novavax is advancing global health through innovative vaccines and has received Emergency Use Authorization for NVX-CoV2373 in Indonesia and the Philippines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.5%
Tags
conferences
-
Rhea-AI Summary

Novavax announced that the European Medicines Agency (EMA) has started evaluating its application for conditional marketing authorization (CMA) of its COVID-19 vaccine, branded as Nuvaxovid™, in the EU. This move aims to enhance global access to the vaccine. Novavax's NVX-CoV2373 vaccine, developed using a nanoparticle protein-based technology, has shown efficacy rates of up to 100% against moderate to severe disease. The company anticipates that the EMA will provide an opinion within weeks, with ongoing regulatory submissions in various countries including the U.S. and Australia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.92%
Tags
covid-19
-
Rhea-AI Summary

Novavax, Inc. (Nasdaq: NVAX) and Serum Institute of India Pvt. Ltd. announced that the Philippine FDA has granted Emergency Use Authorization (EUA) for Novavax's protein-based COVID-19 vaccine, COVOVAX™, which will be produced by SII. The vaccine's approval aims to boost vaccination rates in the Philippines, where less than a third of the population is fully immunized. COVOVAX™ can be stored at standard refrigeration temperatures, facilitating its distribution. Novavax also anticipates additional authorizations globally and plans to submit more filings, including for the U.S. FDA by year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.92%
Tags
covid-19
Rhea-AI Summary

Novavax and SK bioscience have submitted a Biologics License Application (BLA) for NVX-CoV2373, the first protein-based COVID-19 vaccine candidate for BLA in South Korea. This submission signifies the first full approval request for the vaccine globally. Novavax aims to provide broad access to the vaccine, with a deal to supply 40 million doses to the South Korean government. The vaccine shows high efficacy in various trials, promising a vital tool in combating COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
none
-
Rhea-AI Summary

Novavax, Inc. (NASDAQ: NVAX) reported its third-quarter 2021 results with a revenue of $178.8 million, up from $157.0 million year-on-year. The company faced a net loss of $322.4 million or $4.31 per share, compared to a loss of $197.3 million or $3.21 per share last year. Highlights included emergency use authorization for its COVID-19 vaccine in Indonesia and advanced purchase agreements for 20 million doses with the European Commission. Cash reserves as of September 30, 2021, reached $1.9 billion, primarily from advance purchase payments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.27%
Tags
-
Rhea-AI Summary

On November 4, 2021, Novavax (Nasdaq: NVAX) announced the completion of its rolling submission to the World Health Organization (WHO) for emergency use listing (EUL) of its COVID-19 vaccine candidate, NVX-CoV2373. This submission includes clinical data from pivotal Phase 3 trials showing 90.4% overall efficacy. The vaccine demonstrated 100% protection against severe disease and has received authorization in Indonesia. Novavax also plans to submit a complete package to the U.S. FDA by year-end to broaden global access through the COVAX Facility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.27%
Tags
covid-19
Rhea-AI Summary

Novavax has submitted its protein-based COVID-19 vaccine, NVX-CoV2373, for provisional approval to New Zealand's Medsafe, marking a significant step in global vaccine distribution. The submission includes all necessary modules, such as Chemistry, Manufacturing, and Controls (CMC), backed by phase 3 trial data showing 100% protection against moderate and severe disease and 90.4% overall efficacy. With additional regulatory filings in the UK, Australia, and Canada, Novavax is focused on optimizing its global vaccine strategy while thanking the New Zealand government for its partnership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
covid-19
-
Rhea-AI Summary

Novavax, Inc. (Nasdaq: NVAX) and Serum Institute of India have received Emergency Use Authorization (EUA) from Indonesia's National Agency of Drug and Food Control for COVOVAX™, a protein-based COVID-19 vaccine. This marks a significant milestone as it is the first regulatory approval globally for a protein-based COVID-19 vaccine based on Phase 3 clinical data. Novavax expects additional authorizations soon in various countries, including India and the Philippines. The vaccine's stable storage conditions will enhance distribution accessibility in Indonesia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.87%
Tags
covid-19
-
Rhea-AI Summary

Novavax, Inc. (Nasdaq: NVAX) has completed its rolling submission to Health Canada for its COVID-19 vaccine candidate, marking the first protein-based vaccine submitted for regulatory review in Canada. Additionally, all required data modules for the European Medicines Agency (EMA) have been submitted. The vaccine, NVX-CoV2373, showed 100% protection against moderate and severe disease and 90.4% efficacy overall in a Phase 3 trial with 30,000 participants. The company aims to file for Conditional Marketing Authorization in the EU and anticipates submitting a complete package to the U.S. FDA by year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.87%
Tags
covid-19
Rhea-AI Summary

Novavax, Inc. (Nasdaq: NVAX) has completed its rolling submission to the Therapeutic Goods Administration (TGA) for provisional approval of its protein-based COVID-19 vaccine candidate, NVX-CoV2373, in Australia. This marks the first complete application for a protein-based COVID-19 vaccine in the country. The TGA submission includes data from pivotal Phase 3 trials, demonstrating efficacy rates of 96.4% against the original virus strain and 90.4% overall. Novavax plans further submissions in key markets, including the U.S., U.K., and Europe, with a goal to enhance global access to its vaccine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
covid-19
Novavax Inc

Nasdaq:NVAX

NVAX Rankings

NVAX Stock Data

965.07M
146.70M
8.8%
60.18%
24.39%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
GAITHERSBURG